MedPath

Luye Pharma AG

Luye Pharma AG logo
🇩🇪Germany
Ownership
Subsidiary
Established
1997-01-01
Employees
101
Market Cap
-
Website
https://www.luyepharma.eu

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

14

NMPA:6
CIMA_AEMPS:6
SFDA:2

Drug Approvals

Rivastigmine Transdermal Patch

Product Name
利斯的明透皮贴剂
Approval Number
国药准字HJ20200018
Approval Date
Mar 25, 2025
NMPA

Rivastigmine Transdermal Patch

Product Name
利斯的明透皮贴剂
Approval Number
国药准字HJ20200019
Approval Date
Mar 25, 2025
NMPA

Rivastigmine Twice Weekly Transdermal Patch

Product Name
利斯的明透皮贴剂
Approval Number
国药准字HJ20230123
Approval Date
Oct 27, 2023
NMPA

Rivastigmine Twice Weekly Transdermal Patch

Product Name
利斯的明透皮贴剂
Approval Number
国药准字HJ20230124
Approval Date
Oct 27, 2023
NMPA

Rivastigmine Transdermal Patch

Product Name
利斯的明透皮贴剂
Approval Number
H20200019
Approval Date
Jun 2, 2020
NMPA

Rivastigmine Transdermal Patch

Product Name
利斯的明透皮贴剂
Approval Number
H20200018
Approval Date
Jun 2, 2020
NMPA

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.